Calamos Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Calamos Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-110,000	Closed	-$9.65M	–	914
2020 Q4	$9.65M	Buy	110,000 +74,000	+206%	+$5.87M	0.06%	345
2020 Q3	$2.74M	Sell	36,000 -12,000	-25%	-$1.21M	0.02%	554
2020 Q2	$5.92M	Buy	+48,000	New	+$4.77M	0.04%	408

Other funds holding BMRN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Calamos Advisors's BMRN Position: Q2 2022 in Review

Calamos Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 110,000 shares — an estimated $8.48M sold.

Calamos Advisors first reported a position in BMRN in Q2 2013 and held it in 11 quarters. The position peaked at $31.6M in Q3 2016. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

Calamos Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Calamos Advisors sold 110,000 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $8.48M.
Calamos Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 11 quarters.
Calamos Advisors's BioMarin Pharmaceuticals position peaked at $31.6M in Q3 2016.
542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Calamos Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.